CRON Stock Forecast 2025-2026
Distance to CRON Price Targets
CRON Price Momentum
10 Quality Stocks Worth Considering Now
Researching Cronos (CRON) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CRON and similar high-potential opportunities.
Latest CRON Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, CRON has a neutral consensus with a median price target of $1.94 (ranging from $1.70 to $2.18). The overall analyst rating is Buy (6.8/10). Currently trading at $1.77, the median forecast implies a 9.6% upside. This outlook is supported by 2 Buy, 2 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRON Analyst Ratings
CRON Price Target Range
Latest CRON Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRON.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2024 | CIBC | John Zamparo | Outperformer | Maintains | $3.50 |
| Apr 8, 2024 | B of A Securities | Lisa Lewandowski | Underperform | Maintains | $2.50 |
| Dec 28, 2023 | B of A Securities | Lisa Lewandowski | Underperform | Maintains | $2.00 |
| May 15, 2023 | Barclays | Gaurav Jain | Equal-Weight | Maintains | $3.00 |
| Nov 2, 2022 | Bernstein | Nadine Sarwat | Market Perform | Initiates | $3.00 |
| Sep 30, 2022 | Barclays | Gaurav Jain | Equal-Weight | Maintains | $3.50 |
| Mar 22, 2022 | Barclays | Gaurav Jain | Equal-Weight | Upgrade | $0.00 |
| Mar 7, 2022 | Piper Sandler | Michael Lavery | Neutral | Maintains | $3.00 |
| Feb 22, 2022 | Piper Sandler | Michael Lavery | Neutral | Maintains | $4.00 |
| Feb 22, 2022 | Canaccord Genuity | Matt Bottomley | Sell | Maintains | $4.25 |
| Jan 27, 2022 | Jefferies | Owen Bennett | Hold | Upgrade | $3.24 |
| Nov 18, 2021 | Barclays | Underweight | Initiates | $0.00 | |
| Apr 14, 2020 | Piper Sandler | Neutral | Downgrade | $0.00 | |
| Mar 31, 2020 | Canaccord Genuity | Sell | Downgrade | $0.00 | |
| Nov 13, 2019 | B of A Securities | Buy | Maintains | $15.00 | |
| Nov 13, 2019 | Bank of America | Buy | Maintains | $0.00 | |
| Oct 22, 2019 | Piper Jaffray | Overweight | Maintains | $0.00 | |
| Oct 22, 2019 | Piper Sandler | Overweight | Maintains | $12.00 | |
| Aug 13, 2019 | Piper Jaffray | Overweight | Initiates | $0.00 | |
| Aug 13, 2019 | Piper Sandler | Overweight | Initiates | $0.00 |
Cronos Group Inc. (CRON) Competitors
The following stocks are similar to Cronos based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cronos Group Inc. (CRON) Financial Data
Cronos Group Inc. has a market capitalization of $677.08M with a P/E ratio of 16.1x. The company generates $117.62M in trailing twelve-month revenue with a 34.9% profit margin.
Revenue growth is +26.7% quarter-over-quarter, while maintaining an operating margin of -45.3% and return on equity of +3.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Cronos Group Inc. (CRON) Business Model
About Cronos Group Inc.
Vertically integrated cannabis cultivation and distribution.
The company generates revenue through the cultivation, manufacturing, and sale of cannabis products, including flower, oils, and derivatives for both recreational and medicinal uses. It operates across various international markets and leverages strategic partnerships to enhance its market presence while complying with regulatory requirements.
Cronos Group invests significantly in research and development to drive cannabinoid innovation. The company is committed to sustainability and corporate responsibility, contributing to the acceptance of cannabis in the health and wellness sector.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
459
CEO
Mr. Michael Ryan Gorenstein J.D.
Country
Canada
IPO Year
2018
Website
www.thecronosgroup.comCronos Group Inc. (CRON) Latest News & Analysis
Marijuana stocks are currently struggling with low share prices and ongoing declines, despite long-term industry growth and potential. Caution is advised for investors.
Ongoing declines in marijuana stock prices despite industry growth signal volatility, challenging short-term investment decisions while highlighting potential long-term value.
Marijuana stocks are experiencing volatility due to uncertainty in the sector, compounded by tariffs with China affecting packaging and logistics. Caution is advised for future investments.
Volatility in marijuana stocks signals uncertainty, influenced by broader market trends and tariffs affecting logistics, which could impact profitability and investment strategies.
Marijuana stocks are volatile, with many trading at low prices. Over half of cannabis investors are currently at a loss, but the overall industry remains strong despite public sector challenges.
Volatility in marijuana stocks presents both risks and opportunities. Low prices may attract bargain hunters, while overall industry growth suggests potential for future recovery and gains.
Canadian cannabis stocks, including Cronos Group, SNDL Inc., and Aurora Cannabis, are gaining investor interest due to U.S. market exposure and ongoing legalization efforts. The U.S. cannabis market may exceed $45 billion by 2025.
Rising interest in Canadian cannabis stocks reflects potential growth as U.S. legalization expands. Companies with U.S. exposure could benefit significantly from the projected $45 billion market by 2025.
From March 24 to March 28, equity markets faced significant losses, leading to a $100 billion drop in cryptocurrency valuations within 24 hours.
The equity markets' decline and a $100 billion drop in cryptocurrency values signal heightened volatility, which could impact investor sentiment and market stability.
Cronos Stock: Win Big Or Lose All
27 days agoCronos maintains a 'strong buy' rating, highlighting strong fundamentals, 35% revenue growth, reduced EBITDA losses, and positive cash flows, with a focus on international expansion and R&D.
A 'strong buy' rating signals confidence in Cronos, highlighting its revenue growth, improved cash flow, and strategic initiatives, suggesting significant potential for substantial returns.
Frequently Asked Questions About CRON Stock
What is Cronos Group Inc.'s (CRON) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Cronos Group Inc. (CRON) has a median price target of $1.94. The highest price target is $2.18 and the lowest is $1.70.
Is CRON stock a good investment in 2025?
According to current analyst ratings, CRON has 2 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $1.77. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRON stock?
Wall Street analysts predict CRON stock could reach $1.94 in the next 12 months. This represents a 9.6% increase from the current price of $1.77. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cronos Group Inc.'s business model?
The company generates revenue through the cultivation, manufacturing, and sale of cannabis products, including flower, oils, and derivatives for both recreational and medicinal uses. It operates across various international markets and leverages strategic partnerships to enhance its market presence while complying with regulatory requirements.
What is the highest forecasted price for CRON Cronos Group Inc.?
The highest price target for CRON is $2.18 from at , which represents a 23.3% increase from the current price of $1.77.
What is the lowest forecasted price for CRON Cronos Group Inc.?
The lowest price target for CRON is $1.70 from at , which represents a -4.2% decrease from the current price of $1.77.
What is the overall CRON consensus from analysts for Cronos Group Inc.?
The overall analyst consensus for CRON is neutral. Out of 8 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $1.94.
How accurate are CRON stock price projections?
Stock price projections, including those for Cronos Group Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.